Joseph Brandwein

Professor, Faculty of Medicine & Dentistry - Medicine Dept

Contact

Professor, Faculty of Medicine & Dentistry - Medicine Dept
Email
jbrandwe@ualberta.ca
Phone
(780) 407-1584
Address
260H Clinical Sciences Building
11304 - 83 Ave NW
Edmonton AB
T6G 2G3

Overview

Area of Study / Keywords

leukemia chemotherapy drug resistance apoptosis DNA repair acute myeloid leukemia Clinical trial Quality of life analysis


About

Dr. Brandwein is Division Director and Professor in the Division of Hematology, Department of Medicine at the University of Alberta, and Adjunct Professor in the Department of Oncology. He graduated from McGill University Medical School in 1983 and completed his internal medicine residency at Dalhousie University, followed by a hematology residency in Vancouver. He then completed a research fellowship in leukemia and autologous bone marrow transplantation at the Toronto General Hospital. He worked as an academic clinical hematologist at St. Michael’s Hospital in Toronto for nearly ten years. From 2000-2013, he was a clinical investigator in the Department of Medical Oncology and Hematology at Princess Margaret Hospital/University Health Network in Toronto. He joined the faculty at the University of Alberta in August, 2013. 

His major academic focus has been clinical research in acute leukemias and related hematologic malignancies. He has completed a number of investigator-initiated clinical studies evaluating novel treatments for leukemia, and performed extensive evaluations of prognostic factors in AML and ALL. He has over 150 peer-reviewed publications in this area, and has been an invited speaker at numerous national and international meetings. He was the NCIC National Chair of an international clinical trial in AML, and was also the chair and lead author of a national group of leukemia experts that developed consensus guidelines for the treatment of AML in the elderly. He is a member of the executive of the recently formed Canadian Leukemia Study Group.

Dr. Brandwein's  research efforts are directed toward the pre-clinical evaluation of potential new therapeutic approaches in acute leukemia, with a focus on understanding mechanisms of drug resistance and circumventing these, in collaboration with other researchers at the University.  He serves as Director of the Adult Hematology Clinical Research Program at the University of Alberta Hospital, coordinating early and late phase clinical trials across the spectrum of hematology. In addition, he was instrumental in setting up the Marshall Eliuk Fund in Hematology, which promotes clinical research, innovation and fellowship training in Hematology at the University, and serves on its steering committee.

Featured Publications

A Zeidan, P Fenaux, M Gobbi, J Mayer, G Roboz, J Krauter, T Robak, H Kantarjian, J Novak, W Jedrzejczak, X Thomas, M Ojeda-Uribe, Y Miyazaki, Y H Min, S-P Yeh, J Brandwein, L Gercheva, J Demeter, E Griffiths, K Yee, J-P Issa, J Bewersdorf, H Keer, Y Hao, M Azab, and H Döhner.

Blood. 2022 May; 10.1182/blood.2022015832


Rücker F.G., Du L., Luck T.J., Benner A., Krzykalla J., Gathmann I., Voso M.T., Amadori S., Prior T.W., Brandwein J.M., Appelbaum F.R., Medeiros B.C., Tallman M.S., Savoie L., Sierra J., Pallaud C., Sanz M.A., Jansen J.H., Niederwieser D., Fischer T., Ehninger G., Heuser M., Ganser A., Bullinger L., Larson R.A., Bloomfield C.D., Stone R.M., Döhner H., Thiede C., Döhner K.

Leukemia. 2022 January; 36 (1):90-99 10.1038/s41375-021-01323-0


A Phase 2 Open-Label, Multicenter, Dose Optimization Clinical Study of the Safety, Tolerability, and Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Cfi-400945 As a Single Agent or in Combination with Azacitidine or Decitabine in Patients with Acute Myeloid Leukemia

American Society of Hematology Annual Meeting 2020. 2021 December;


Comparative Results of Azacitidine and Decitabine from a Large Prospective Phase 3 Study in Treatment Naive Patients with Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

American Society of Hematology Annual Meeting 2020. 2021 December;


CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study.

American Society of Hematology Annual Meeting 2020. 2021 December;


Molecular Landscape and Prognostic Impact of FLT3 Internal Tandem Duplication Insertion Site in Acute Myeloid Leukemia (AML): Results from the Ratify Study (Alliance 10603).

American Society of Hematology Annual Meeting 2020. 2021 December;


162. De Botton S; Brandwein J; Wei,A ; Pigneux A; Quesnel B; Thomas X; Legrand O; Recher C; Chantepie S; Hunault M; Boissel N; Nehme S ; Frattini M; Tosolini A; Marion-Gallois R; Wang J; Cameron C; Siddiqui M; Hutton B; Milkovich G; Stein E.

Cancer Medicine. 2021 September; 10 (18):6336-6343 10.1002/cam4.4182. Epub 2021 Aug 24.PMID: 34427990


Mohseni M., Kucharski C., Remant Bahadur K.C., Nasrullah M., Jiang X., Uludag H., Brandwein J.

PLoS ONE. 2021 June; 16 (6 June) 10.1371/journal.pone.0251719


Daver N., Salhotra A., Brandwein J.M., Podoltsev N.A., Pollyea D.A., Jurcic J.G., Assouline S., Yee K., Li M., Pourmohamad T., Samineni D., Sumiyoshi T., Vaze A., Dere R.C., Ma C., Cooper J.

American Journal of Hematology. 2021 May; 96 (5):E175-E179 10.1002/ajh.26136


Bozorgmehr N., Okoye I., Oyegbami O., Xu L., Fontaine A., Cox-Kennett N., Larratt L.M., Hnatiuk M., Fagarasanu A., Brandwein J., Peters A.C., Elahi S.

Journal for ImmunoTherapy of Cancer. 2021 April; 9 (4) 10.1136/jitc-2020-002189


Brandwein J.M., Hallett D., Karkhaneh M., Zhu N., Liew E., Bolster L., Hamilton M., Patterson J., Taparia M., Wu C., Van Slyke T., Bankar A., Saini L.

American Journal of Hematology. 2021 January; 96 (1):E17-E20 10.1002/ajh.26012


Larson R.A., Mandrekar S.J., Huebner L.J., Sanford B.L., Laumann K., Geyer S., Bloomfield C.D., Thiede C., Prior T.W., Döhner K., Marcucci G., Voso M.T., Klisovic R.B., Galinsky I., Wei A.H., Sierra J., Sanz M.A., Brandwein J.M., de Witte T., Niederwieser D., Appelbaum F.R., Medeiros B.C., Tallman M.S., Krauter J., Schlenk R.F., Ganser A., Serve H., Ehninger G., Amadori S., Gathmann I., Döhner H., Stone R.M.

Leukemia. 2021 January; 10.1038/s41375-021-01179-4


Comparative Results of Azacitidine and Decitabine from a Large Prospective Phase 3 Study in Treatment Naive Patients with Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy.

American Society of Hematology Annual Meeting 2020. 2020 December;


CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study.

American Society of Hematology Annual Meeting 2020. 2020 December;


Molecular Landscape and Prognostic Impact of FLT3 Internal Tandem Duplication Insertion Site in Acute Myeloid Leukemia (AML): Results from the Ratify Study (Alliance 10603).

American Society of Hematology Annual Meeting 2020. 2020 December;


Tolerability, and Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Cfi-400945 As a Single Agent or in Combination with Azacitidine or Decitabine in Patients with Acute Myeloid Leukemia.

American Society of Hematology Annual Meeting 2020. 2020 December;


Voso M.T., Larson R.A., Jones D., Marcucci G., Prior T., Krauter J., Heuser M., Lavorgna S., Nomdedeu J., Geyer S.M., Walker A., Wei A.H., Sierra J., Sanz M.A., Brandwein J.M., de Witte T.M., Jansen J.H., Niederwieser D., Appelbaum F.R., Medeiros B.C., Tallman M.S., Schlenk R.F., Ganser A., Amadori S., Cheng Y., Chen Y.M., Pallaud C., Du L., Piciocchi A., Ehninger G., Byrd J., Thiede C., Döhner K., Stone R.M., Döhner H., Bloomfield C.D., Lo-Coco F.

Blood Advances. 2020 October; 4 (19):4945-4954 10.1182/BLOODADVANCES.2020002904